Control of human β-globin mRNA stability and its impact on beta-thalassemia phenotype

Haematologica

Volumn 96, Issue 6, 2011, Pages 905-913

  Peixeiro, Isabel ^a   Silva, Ana Luísa ^a   Romão, Luísa ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Beta globin; Beta thalassemia; Clinical phenotype; MRNA quality control; MRNA stability; Nonsense mediated mRNA decay (NMD)

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; MESSENGER RNA; RIBONUCLEOPROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BETA THALASSEMIA; COMPLEX FORMATION; DISEASE SEVERITY; FRAMESHIFT MUTATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GENETIC CONSERVATION; HALF LIFE TIME; HUMAN; MUTATIONAL ANALYSIS; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PHENOTYPE; POLYADENYLATION; RNA STABILITY; RNA TRANSLATION; TRANSCRIPTION REGULATION;

BETA-GLOBINS; BETA-THALASSEMIA; GENE EXPRESSION REGULATION; HUMANS; MUTATION; PHENOTYPE; RIBONUCLEOPROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 79958192752     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039206     Document Type: Article

References (88)

1. Ross J. mRNA stability in mammalian cells. Microbiol Rev. 1995;59(3):423-50.
2. Sachs AB, Sarnow P, Hentze MW. Starting at the beginning, middle, and end: translation initiation in eukaryotes. Cell. 1997;89(6): 831-8.
3. Russell JE, Morales J, Liebhaber SA. The role of mRNA stability in the control of globin gene expression. Prog Nucleic Acid Res Mol Biol. 1997;57:249-87.
4. Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. Gene. 2001;265(1-2):11-23.
5. Tomecki R, Drazkowska K, Dziembowski A. Mechanisms of RNA degradation by the eukaryotic exosome. Chembiochem. 2010; 11(7):938-45.
6. Li XA, Beebe DC. Messenger RNA stabilization in chicken lens development: a reexamination. Dev Biol. 1991;146(1):239-41.
7. Hamalainen L, Oikarinen J, Kivirikko KI. Synthesis and degradation of type I procollagen mRNAs in cultured human skin fibroblasts and the effect of cortisol. J Biol Chem. 1985;260(2):720-5.
8. Aviv H, Voloch Z, Bastos R, Levy S. Biosynthesis and stability of globin mRNA in cultured erythroleukemic Friend cells. Cell. 1976;8(4):495-503.
9. Ross J, Sullivan TD. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood. 1985;66(5):1149-54.
10. Jacobson A, Peltz SW. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem. 1996;65:693-739.
11. Bastos RN, Aviv H. Theoretical analysis of a model for globin messenger RNA accumulationduring erythropoiesis. J Mol Biol. 1977; 110(2):205-18.
12. Bastos RN, Volloch Z, Aviv H. Messenger RNA population analysis during erythroid differentiation: a kinetical approach. J Mol Biol. 1977;110(2):191-203.
13. Inacio A, Silva AL, Pinto J, Ji X, Morgado A, Almeida F, et al. Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay. J Biol Chem. 2004;279(31):32170-80.
14. Clegg JB, Weatherall DJ, Milner PF. Haemoglobin Constant Spring--a chain termination mutant¿ Nature. 1971;234(5328): 337-40.
15. Waggoner SA, Liebhaber SA. Regulation of alpha-globin mRNA stability. Exp Biol Med (Maywood). 2003;228(4):387-95.
16. Liebhaber SA, Kan YW. alpha-Thalassemia caused by an unstable alpha-globin mutant. J Clin Invest. 1983;71(3):461-6.
17. Morales J, Russell JE, Liebhaber SA. Destabilization of human alpha-globin mRNA by translation anti-termination is controlled during erythroid differentiation and is paralleled by phased shortening of the poly(A) tail. J Biol Chem. 1997;272(10):6607-13.
18. Wang X, Kiledjian M, Weiss IM, Liebhaber SA. Detection and characterization of a 3' untranslated region ribonucleoprotein complex associated with human alpha-globin mRNA stability. Mol Cell Biol. 1995;15(3): 1769-77.
19. Kiledjian M, Wang X, Liebhaber SA. Identification of two KH domain proteins in the alpha-globin mRNP stability complex. EMBO J. 1995;14(17):4357-64.
20. Kong J, Ji X, Liebhaber SA. The KH-domain protein alpha CP has a direct role in mRNA stabilization independent of its cognate binding site. Mol Cell Biol. 2003;23(4):1125-34.
21. Wang Z, Kiledjian M. The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Mol Cell Biol. 2000;20(17):6334-41.
22. Rodgers ND, Wang Z, Kiledjian M. Regulated alpha-globin mRNA decay is a cytoplasmic event proceeding through 3'-to- 5' exosome-dependent decapping. RNA. 2002;8(12):1526-37.
23. Flatz G, Kinderlerer JL, Kilmartin JV, Lehmann H. Haemoglobin Tak: a variant with additional residues at the end of the beta-chains. Lancet. 1971;1(7702):732-3.
24. Imai K, Lehmann H. The oxygen affinity of haemoglobin Tak, a variant with an elongated beta chain. Biochim Biophys Acta. 1975;412(2):288-94.
25. Tanphaichitr VS, Viprakasit V, Veerakul G, Sanpakit K, Tientadakul P. Homozygous hemoglobin Tak causes symptomatic secondary polycythemia in a Thai boy. J Pediatr Hematol Oncol. 2003;25(3):261-5.
26. Jankovic L, Dimovski AJ, Kollia P, Karageorga M, Loukopoulos D, Huisman TH. A C----G mutation at nt position 6 3' to the terminating codon may be the cause of a silent beta-thalassemia. Int J Hematol. 1991;54(4):289-93.
27. Bilenoglu O, Basak AN, Russell JE. A 3'UTR mutation affects beta-globin expression without altering the stability of its fully processed mRNA. Br J Haematol. 2002;119 (4):1106-14.
28. Cai SP, Eng B, Francombe WH, Olivieri NF, Kendall AG, Waye JS, et al. Two novel betathalassemiamutations in the 5' and 3' noncoding regions of the beta-globin gene. Blood. 1992;79(5):1342-6.
29. Rund D, Filon D, Dowling C, Kazazian HH Jr, Rachmilewitz EA, Oppenheim A. Molecular studies of beta-thalassemia in Israel. Mutational analysis and expression studies. Ann NY Acad Sci. 1990;612:98-105.
30. Ghanem N, Girodon E, Vidaud M, Martin J, Fanen P, Plassa F, et al. A comprehensive scanning method for rapid detection of betaglobin gene mutations and polymorphisms. Hum Mutat. 1992;1(3):229-39.
31. Jankovic L, Efremov GD, Petkov G, Kattamis C, George E, Yang KG, et al. Two novel polyadenylation mutations leading to beta(+)-thalassemia. Br J Haematol. 1990;75 (1):122-6.
32. Orkin SH, Cheng TC, Antonarakis SE, Kazazian HH Jr. Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene. EMBO J. 1985;4(2):453-6.
33. Proudfoot NJ. Genetic dangers in poly(A) signals. EMBO Rep. 2001;2(10):891-2.
34. Kabnick KS, Housman DE. Determinants that contribute to cytoplasmic stability ofhuman c-fos and beta-globin mRNAs are located at several sites in each mRNA. Mol Cell Biol. 1988;8(8):3244-50.
35. Weiss IM, Liebhaber SA. Erythroid cell-specific mRNA stability elements in the alpha 2- globin 3' nontranslated region. Mol Cell Biol. 1995;15(5):2457-65.
36. Russell JE, Liebhaber SA. The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3' untranslated region. Blood. 1996;87(12): 5314-23.
37. Weiss IM, Liebhaber SA. Erythroid cell-specific determinants of alpha-globin mRNA stability. Mol Cell Biol. 1994;14(12):8123-32.
38. Sgourou A, Papachatzopoulou A, Psiouri L, Antoniou M, Zoumbos N, Gibbs R, et al. The beta-globin C→G mutation at 6 bp 3' to the termination codon causes beta-thalassaemia by decreasing the mRNA level. Br J Haematol. 2002;118(2):671-6.
39. Yu J, Russell JE. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 2001;21(17):5879-88.
40. Chen CY, Shyu AB. Rapid deadenylation triggered by a nonsense codon precedes decay of the RNA body in a mammalian cytoplasmic nonsense-mediated decay pathway. Mol Cell Biol. 2003;23(14):4805-13.
41. Stolle CA, Benz EJ Jr. Cellular factor affecting the stability of beta-globin mRNA. Gene. 1988;62(1):65-74.
42. Jiang Y, Xu XC, Russell JE. A Nucleolin- Binding 3' Untranslated Region Element Stabilizes β-Globin mRNA In Vivo. Mol Cell Biol. 2006;26(6):2419-29.
43. Moore MJ. From birth to death: the complex lives of eukaryotic mRNAs. Science. 2005;309(5740):1514-8.
44. Silva AL, Romao L. The mammalian nonsense- mediated mRNA decay pathway: to decay or not to decay! Which players make the decision? FEBS Lett. 2009;583(3):499- 505.
45. Vasudevan S, Peltz SW, Wilusz CJ. Non-stop decay--a new mRNA surveillance pathway. Bioessays. 2002;24(9):785-8.
46. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol. 2007;8(2):113-26.
47. Stalder L, Muhlemann O. The meaning of nonsense. Trends Cell Biol. 2008;18(7):315- 21.
48. Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE. NMD: RNA biology meets human genetic medicine. Biochem J. 2010;430(3):365-77.
49. Kong J, Liebhaber SA. A cell type-restricted mRNA surveillance pathway triggered by ribosome extension into the 3' untranslated region. Nat Struct Mol Biol. 2007;14(7):670-6.
50. Voon HP, Vadolas J. Controlling alpha-globin: a review of alpha-globin expression and its impact on beta-thalassemia. Haematologica. 2008;93(12):1868-76.
51. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet. 2004;36 (8):801-8.
52. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene. 2002;299(1-2):1-34.
53. Maquat LE. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol. 2004;5(2): 89-99.
54. Conti E, Izaurralde E. Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol. 2005;17(3):316-25.
55. Bhattacharya A, Czaplinski K, Trifillis P, He F, Jacobson A, Peltz SW. Characterization of the biochemical properties of the human Upf1 gene product that is involved in nonsense- mediated mRNA decay. RNA. 2000;6 (9):1226-35.
56. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, et al. Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol Cell. 2003;12(5):1187-200.
57. Singh G, Lykke-Andersen J. New insights into the formation of active nonsense-mediated decay complexes. Trends Biochem Sci. 2003;28(9):464-6.
58. Behm-Ansmant I, Kashima I, Rehwinkel J, Sauliere J, Wittkopp N, Izaurralde E. mRNA quality control: an ancient machinery recognizes and degrades mRNAs with nonsense codons. FEBS Lett. 2007;581(15):2845-53.
59. Hwang J, Sato H, Tang Y, Matsuda D, Maquat LE. UPF1 association with the capbinding protein, CBP80, promotes nonsense-mediated mRNA decay at two distinct steps. Mol Cell. 2010;39(3):396-409.
60. Song H, Mugnier P, Das AK, Webb HM, Evans DR, Tuite MF, et al. The crystal structure of human eukaryotic release factor eRF1--mechanism of stop codon recognition and peptidyl-tRNA hydrolysis. Cell. 2000; 100(3):311-21.
61. Frolova L, Le Goff X, Zhouravleva G, Davydova E, Philippe M, Kisselev L. Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase. RNA. 1996;2(4): 334-41.
62. Eberle AB, Stalder L, Mathys H, Orozco RZ, Muhlemann O. Posttranscriptional gene regulation by spatial rearrangement of the 3' untranslated region. PLoS Biol. 2008;6(4): e92.
63. Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. PLoS Biol. 2008;6(4):e111.
64. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, et al. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev. 2006;20(3):355-67.
65. Silva AL, Ribeiro P, Inacio A, Liebhaber SA, Romao L. Proximity of the poly(A)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay. RNA. 2008;14(3):563-76.
66. Kashima I, Jonas S, Jayachandran U, Buchwald G, Conti E, Lupas AN, et al. SMG6 interacts with the exon junction complex via two conserved EJC-binding motifs (EBMs) required for nonsense-mediated mRNA decay. Genes Dev. 2010;24(21):2440-2450.
67. Eberle AB, Lykke-Andersen S, Muhlemann O, Jensen TH. SMG6 promotes ndonucleolytic cleavage of nonsense mRNA in human cells. Nat Struct Mol Biol. 2009;16(1):49-55.
68. Huisman TH. The structure and function of normal and abnormal haemoglobins. Baillieres Clin Haematol. 1993;6(1):1-30.
69. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J. 2000;19(24):6860-9.
70. Le Hir H, Moore MJ, Maquat LE. Pre-mRNA splicing alters mRNP composition: evidence for stable association of proteins at exonexon junctions. Genes Dev. 2000;14(9):1098-1108.
71. Zhang J, Sun X, Qian Y, Maquat LE. Intron function in the nonsense-mediated decay ofbeta-globin mRNA: indications that premRNA splicing in the nucleus can influence mRNA translation in the cytoplasm. RNA. 1998;4(7):801-15.
72. Thermann R, Neu-Yilik G, Deters A, Frede U, Wehr K, Hagemeier C, et al. Binary specification of nonsense codons by splicing and cytoplasmic translation. EMBO J. 1998;17 (12):3484-94.
73. Romao L, Inacio A, Santos S, Avila M, Faustino P, Pacheco P, et al. Nonsense mutations in the human beta-globin gene lead to unexpected levels of cytoplasmic mRNA accumulation. Blood. 2000;96(8):2895-901.
74. Baserga SJ, Benz EJ Jr. Nonsense mutations n the human beta-globin gene affect mRNA metabolism. Proc Natl Acad Sci USA. 1988;85(7):2056-60.
75. Divoky V, Gu LH, Indrak K, Mocikova K, Zarnovicanova M, Huisman TH. A new beta zero-thalassaemia nonsense mutation (codon 112, T-->A) not associated with a dominant type of thalassaemia in the heterozygote. Br J Haematol. 1993;83(3):523-4.
76. Hall GW, Thein S. Nonsense codon mutations in the terminal exon of the beta-globin gene are not associated with a reduction in beta-mRNA accumulation: a mechanism for the phenotype of dominant beta-thalassemia. Blood. 1994;83(8):2031-7.
77. Neu-Yilik G, Gehring NH, Thermann R, Frede U, Hentze MW, Kulozik AE. Splicing and 3' end formation in the definition of nonsense-mediated decay-competent human beta-globin mRNPs. EMBO J. 2001;20(3):532-40.
78. Zhang J, Sun X, Qian Y, LaDuca JP, Maquat LE. At least one intron is required for the onsense-mediated decay of triosephosphate isomerase mRNA: a possible linkbetween nuclear splicing and cytoplasmic translation. Mol Cell Biol. 1998;18(9):5272-83.
79. Sun X, Maquat LE. mRNA surveillance in mammalian cells: the relationship between ntrons and translation termination. RNA. 2000;6(1):1-8.
80. Ruiz-Echevarria MJ, Gonzalez CI, Peltz SW. Identifying the right stop: determining how the surveillance complex recognizes and degrades an aberrant mRNA. EMBO J. 1998;17(2):575-89.
81. Maquat LE, Carmichael GG. Quality control of mRNA function. Cell. 2001;104(2):173-6.
82. Silva AL, Pereira FJ, Morgado A, Kong J, Martins R, Faustino P, et al. The canonical UPF1-dependent nonsense-mediated mRNA decay is inhibited in transcripts carrying a short open reading frame independent of sequence context. RNA. 2006;12(12):2160-70.
83. Zhang J, Maquat LE. Evidence that translation reinitiation abrogates nonsense-mediated mRNA decay in mammalian cells. EMBO J. 1997;16(4):826-33.
84. Inacio A, Silva AL, Morgado A, Pereira FJ, Lavinha J, Romao L. Comment on 'Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease'. Eur J Hum Genet. 2007 May;15(5):533-4; author reply 534.
85. Danckwardt S, Neu-Yilik G, Thermann R, Frede U, Hentze MW, Kulozik AE. Abnormally spliced beta-globin mRNAs: a single point mutation generates transcripts sensitive and insensitive to nonsense-mediated mRNA decay. Blood. 2002;99(5):1811- 6.
86. Cao A, Gossens M, Pirastu M. Beta thalassaemia mutations in Mediterranean populations. Br J Haematol. 1989;71(3):309-12.
87. Khajavi M, Inoue K, Lupski JR. Nonsensemediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet. 2006;14(10):1074-81.
88. Kuzmiak HA, Maquat LE. Applying nonsense- mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med. 2006;12(7):306-16.